{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:05:52Z","timestamp":1779696352574,"version":"3.53.1"},"reference-count":20,"publisher":"Scientific Scholar","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>In this study, we aimed to reveal the incidence of \u22653 focal lesions (FLs) and analyze overall survival (OS) and progression-free survival (PFS) according to the number of FLs, as well as to identify mortality and PFS risk factors, in our newly diagnosed multiple myeloma (NDMM) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 89 NDMM patients who underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG positron emission tomography\/computerized tomography (PET\/CT) imaging were included in the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      While 57.3% of the patients had \u22653 FLs, 20.2% had no FL. The median OS and PFS were 55 and 43 months, respectively. The median survival time was 49 months for patients with \u22653 FLs and 101 months for patients with &lt;3 FLs, with a statistically significant difference (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.049). The median PFS was 34 months in patients with \u22653 FLs and 67 months in patients with &lt;3 FLs; this difference was also statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.026). The difference in median survival was statistically significant, based on whether autologous stem cell transplantation (ASCT) was performed and the number of FLs (\u22653 or &lt;3) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011). In the multivariate regression analysis, \u22653 FLs was not a predictor of mortality but was a risk factor for PFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      In our study, we observed significantly worse OS and PFS in patients with \u22653 FLs at diagnosis, and it is noteworthy that the OS was worse in those patients who did not undergo ASCT.\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT is a feasible imaging technique for the prediction of prognosis in the initial evaluation of NDMM, and we believe that consolidation with ASCT as a modifiable factor, especially in patients with \u22653 FLs, will lead to a more favorable prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijnm.ijnm_131_24","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T08:00:35Z","timestamp":1737964835000},"page":"353-359","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Focal Lesions on Overall and Progression-free Survival in Multiple Myeloma"],"prefix":"10.25259","volume":"39","author":[{"given":"Tugcan Alp","family":"Kirkizlar","sequence":"first","affiliation":[{"name":"Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Kirkizlar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Soyluoglu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Trakya University Medical Faculty, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Gulsum","family":"Umit","sequence":"additional","affiliation":[{"name":"Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Ustun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Trakya University Medical Faculty, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Muzaffer","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Hematology, Trakya University Medical Faculty, Edirne, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"R1-20250127","doi-asserted-by":"crossref","first-page":"17046.","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"R3-20250127","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.semnuclmed.2022.10.008","article-title":"Clinical value of FDG-PET\/CT in multiple myeloma: An update","volume":"53","author":"Bezzi","year":"2023","journal-title":"Semin Nucl Med"},{"key":"R4-20250127","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"R5-20250127","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"R6-20250127","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00330-020-07177-x","article-title":"Prognostic value of (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography in newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"31","author":"Han","year":"2021","journal-title":"Eur Radiol"},{"key":"R7-20250127","first-page":"31","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin Exp Med"},{"key":"R8-20250127","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18) F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the international myeloma working group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"R9-20250127","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ejrad.2014.09.012","article-title":"State of the art imaging of multiple myeloma: Comparative review of FDG PET\/CT imaging in various clinical settings","volume":"83","author":"Mesguich","year":"2014","journal-title":"Eur J Radiol"},{"key":"R10-20250127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-014-0308-3","article-title":"\u00b9\u2078F\u2013FDG PET\/CT: A review of diagnostic and prognostic features in multiple myeloma and related disorders","volume":"15","author":"Dammacco","year":"2015","journal-title":"Clin Exp Med"},{"key":"R11-20250127","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"R12-20250127","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R13-20250127","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"R14-20250127","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R15-20250127","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"R16-20250127","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"R17-20250127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","article-title":"(18) F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised international staging system","volume":"46","author":"Jung","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-20250127","doi-asserted-by":"crossref","first-page":"190.","DOI":"10.1038\/s41408-021-00577-2","article-title":"Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18) F-FDG PET\/CT","volume":"11","author":"Cho","year":"2021","journal-title":"Blood Cancer J"},{"key":"R19-20250127","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"key":"R20-20250127","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.14827","article-title":"Guidelines for the use of imaging in the management of patients with myeloma","volume":"178","author":"Chantry","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Indian Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijnm.ijnm_131_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:38:18Z","timestamp":1779694698000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijnm.co.in\/the-impact-of-focal-lesions-on-overall-and-progression-free-survival-in-multiple-myeloma\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijnm.ijnm_131_24","relation":{},"ISSN":["0972-3919","0974-0244"],"issn-type":[{"value":"0972-3919","type":"print"},{"value":"0974-0244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2024-09-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}